Prefilled Syringes Market: A Safer, Quicker & Easier Method of Drug Delivery

The Global Prefilled Syringes Market is expected to witness a high single-digit growth rate by 2027. The growth of the prefilled syringes market is driven by an increasing prevalence of diverse chronic diseases, a growing biologics and biosimilars market, a rising aging population, growing adoption of self-injecting parenteral devices, development of advanced, safe & convenient self-injectable syringes and supporting government regulations.

Download Sample Brochure: https://meditechinsights.com/prefilled-syringes-market/request-sample/

The prefilled syringes market refers to the global industry involved in producing and distributing syringes that come pre-filled with medication or vaccines. Prefilled syringes offer various advantages, including accurate dosing, reduced risk of contamination, and ease of use, making them a popular choice for both healthcare providers and patients. There are different types of prefilled syringes, including glass and plastic syringes. The choice of syringe material depends on the medication and intended use. Prefilled syringes are used for various medications, including vaccines, insulin, anticoagulants, and biologics. They are also used in emergency medicine and for self-administration by patients with conditions like diabetes. They can improve patient compliance, reduce the risk of needlestick injuries, and minimize drug wastage. Prefilled syringes are also tamper-evident, enhancing medication security.

The Expanding Role of Prefilled Syringes in Modern Medicine

The prefilled syringes market is driven by factors such as the rise in home care services, particularly among aging populations and individuals with chronic conditions, which has led to an escalated demand for prefilled syringes. These syringes are designed for ease of use and reduce the necessity for healthcare professionals to administer injections, making them a highly suitable choice for home care settings.

Prefilled syringes offer a user-friendly and convenient solution for patients requiring regular injections, especially for conditions like diabetes, rheumatoid arthritis, and multiple sclerosis, where self-administration at home is common. Moreover, the reduced potential for medication errors is a crucial benefit. Prefilled syringes come pre-measured and pre-filled, minimizing the risk of dosing errors, thereby enhancing patient safety and ensuring accurate dosage administration, which makes them the preferred option over other syringes.

The increased utilization of biological drugs is another driving force. These drugs often demand precise and convenient injection methods, making prefilled syringes the ideal choice, given their suitability for delivering biologics that are increasingly used in treating various medical conditions.

Technological advancements, including innovations in syringe design, materials, safety features, and needle technologies, have enhanced the performance and usability of prefilled syringes, and their global adoption. Furthermore, regulatory support from agencies like the FDA and EMA, recognizing the safety and convenience of prefilled syringes, further boosts the market growth. For instance,

• In May 2023, Nexus Pharmaceuticals obtained FDA approval for single-dose prefilled syringes of Emerphed® (ephedrine sulfate injection), an essential treatment for significant hypotension during anesthesia. The approval covers two variants, 25mg/5mL and 50mg/10mL. The 10mL syringe is the first and only FDA-sanctioned ready-to-administer prefilled syringe in its class

Rising Demand for Prefilled Syringes: A Response to Global Health Needs

Prefilled syringes have a crucial role in reducing the risk of drug contamination. The conventional method of using a syringe to withdraw a dose from a drug vial inherently carries the potential for contamination due to unintentional mixing. The introduction of pre-sterilized syringes eliminates this risk, enhancing safety measures and eliminating the requirement for on-site vial cleaning and de-pyrogenation, marking a substantial advancement in this regard.

Autoimmune disorders, diabetes, and certain types of cancers can now be effectively managed through the use of auto-injectors and prefilled glass syringes. With the continuous advancements in drug technologies, especially in the realm of biologics, prefilled glass syringes and auto-injectors are becoming indispensable tools for supporting patients in their self-administration of medications outside clinical and hospital settings. For instance,

• In September 2022, BD (Becton, Dickinson and Company) unveiled an advanced glass prefillable syringe (PFS) that establishes a fresh benchmark in performance for vaccine PFS, featuring enhanced specifications for processability, aesthetics, contamination, and integrity. The innovative BD EffivaxTM Glass Prefillable Syringe was developed in partnership with prominent pharmaceutical firms to address the intricate and evolving requirements of vaccine production

The increasing global prevalence of diabetes stands out as a significant driving force behind the growing demand for prefilled syringes. Diabetes has emerged as a critical public health challenge with far-reaching implications for both public health and socioeconomic well-being. Patients with diabetes often rely on prefilled syringes to administer multiple insulin doses daily. The substantial patient population, the rising incidence of diabetes, and the demand for improved and safer insulin delivery devices are some of the key factors that are expected to drive the market in the coming years.

The emergence of the COVID-19 pandemic and the associated constraints made it challenging for patients to access healthcare facilities. To address these challenges, pharmaceutical companies have introduced self-administered dosage forms to simplify the overall treatment process. It's important to note that the increasing global population, coupled with a shortage of healthcare resources, has paved the way for a broader adoption of self-administered dosage forms like prefilled syringes among patients. The urgency to develop vaccines and treatments for COVID-19 has driven significant impetus to the prefilled syringe market, fostering innovations in syringe design and fill/finish operations. Prefilled syringes streamline the injection process, reduce the risk of injury and cross-contamination, and offer enhanced dose accuracy.

North America Accounts for the Largest Share of the Global Market

The size of the market varies across regions, with typically more well-established services in developed countries. North America and Europe stand out as two of the largest markets for prefilled syringes market. Within the global market, North America takes the lead, primarily owing to the existence of an established prefilled syringe industry, driven by a robust presence of pharmaceutical and biotechnology firms. The increasing preference for self-administered medications is a key driver behind the growing demand for prefilled syringes in the region.

However, the Asia-Pacific region is experiencing rapid expansion in the prefilled syringe market, attributed to the growing healthcare infrastructure and an aging population. Countries like India and China, offering lower manufacturing costs, have become significant production and supply hubs, fueling market growth. Moreover, the market landscape is evolving as biologics and biosimilars gain traction in the region.

Competitive Landscape

Prominent companies competing currently in the global prefilled syringes market are Gerresheimer AG, West Pharmaceutical Services Inc., BD, Abbott Laboratories, Bayer AG, Baxter International, NIPRO Pharma, TERUMO PHARMACEUTICAL SOLUTIONS, Stevanato Group, Pfizer Inc., and Catalent, Inc.

Download Sample Brochure: https://meditechinsights.com/prefilled-syringes-market/request-sample/

Organic and Inorganic Growth Strategies Adopted by Players to Establish Their Foothold in the Market

Players operating in this market are adopting both organic and inorganic growth strategies such as entering into collaborations, acquiring related firms, and expanding manufacturing capabilities to garner market share. For instance,

• In March 2023, Stevanato Group partnered with Recipharm to co-develop and manufacture pre-fillable syringes designed for a new Soft Mist Inhaler tailored for sensitive biological products. This collaboration includes Stevanato Group offering manufacturing assistance for the production of these syringes, employing its Alba® glass pre-fillable syringe combined with Recipharm's Integrated Spray Module (ISMTM) technology for their Soft Mist Inhaler, referred to as the Pre-Filled Syringe Inhaler (PFSITM)

The market is expected to continue to grow due to the rising aging population, growing awareness related to the benefits of prefilled syringes among patients & healthcare professionals, technological innovations, and aggressive organic and inorganic growth strategies followed by the players.